A phase 3, randomized, double-blind, multicenter study comparing oral MLN9708 plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. NCT01564537
A randomized, multicenter, phase 3 study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) vs lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma. NCT01080391
A randomized, open-label phase 3 study of carfilzomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible patients with newly diagnosed multiple myeloma. NCT01818752
A randomized, open-label, phase 3 study of carfilzomib plus dexamethasone vs bortezomib plus dexamethasone in patients with relapsed multiple myeloma. NCT01568866
A randomized, open-label, phase 3 study of carfilzomib vs best supportive care in subjects with relapsed and refractory multiple myeloma. NCT01302392
Arnulf B et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012;97(12):1925-8. Abstract
Attal M et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782-91. Abstract
Bringhen S et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116(23):4745-53. Abstract
Cavo M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 2010;376(9758):2075-85. Abstract
Davies FE et al. Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM) — Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial. Proc ASCO 2011;Abstract 8011.
Dimopoulos MA et al. Pomalidomide in combination with low-dose dexamethasone: Demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: A phase 3, multicenter, randomized, open-label study. Proc ASH 2012;Abstract LBA-6.
Fostier K et al. Carfilzomib: A novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ther 2012;5:237-44. Abstract
Henry DH et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29(9):1125-32. Abstract
Jakubowiak AJ et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120(9):1801-9. Abstract
Kumar SK et al. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). Proc ASH 2012;Abstract 332.
Lonial S et al. Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM). Proc ASCO 2012;Abstract 8017.
Ludwig H et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012;119(13):3003-15. Abstract
McCarthy PL et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1770-81. Abstract
Moreau P et al. The future of therapy for relapsed/refractory multiple myeloma: Emerging agents and novel treatment strategies. Semin Hematol 2012;49:Suppl 1:33-46. Abstract
Moreau P et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12(5):431-40. Abstract
Moreau P et al. A phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma. Proc ASH 2010;Abstract 312.
Morgan GJ et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): Secondary outcomes from a randomised controlled trial. Lancet Oncol 2011;12(8):743-52. Abstract
Morgan GJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 2010;376(9757):1989-99. Abstract
Palumbo A et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN). Blood 2011;118(17):4519-29. Abstract
Palumbo A et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J Clin Oncol 2010;28(34):5101-9. Abstract
Palumbo A et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22(2):414-23. Abstract
Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86(1):57-65. Abstract
Reeder CB et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115(16):3416-7. Abstract
Reeder CB et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial. Leukemia 2009;23(7):1337-41. Abstract
Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679-86. Abstract
Rosinol L et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study. Blood 2012;120(8):1589-96. Abstract
Rosinol L et al. A phase III PETHEMA/GEM randomized trial of postransplant (ASCT) maintenance in multiple myeloma: Superiority of bortezomib/thalidomide compared with thalidomide and alfa-2b interferon. Proc ASH 2011;Abstract 3962.
Siegel DS et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120(14):2817-25. Abstract
Sonneveld P et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012;30(24):2946-55. Abstract
Warren JL et al. Multiple myeloma treatment transformed: A population-based study of changes in initial management approaches in the United States. J Clin Oncol 2013;31(16):1984-9.Abstract